Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutions's change in inventory for the quarter that ended in Jun. 2026 was $24.0 Mil. It means Emergent BioSolutions's inventory
declined by $24.0 Mil
from Mar. 2026 to Jun. 2026 .
Emergent BioSolutions's change in inventory for the fiscal year that ended in Dec. 2025 was $-30.3 Mil. It means Emergent BioSolutions's inventory
increased by $30.3 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Emergent BioSolutions's Days Inventory for the quarter that ended in Jun. 2026 was 296.59.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Emergent BioSolutions's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emergent BioSolutions's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 1.39.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Emergent BioSolutions's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Change In Inventory Related Terms
Emergent BioSolutions Change In Inventory Historical Data
* Premium members only.
The historical data trend for Emergent BioSolutions's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $36.4 Mil mean?
Emergent BioSolutions (EBS) has a Change In Inventory of $36.4 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Change In Inventory too high?
Emergent BioSolutions' current Change In Inventory is $36.4 Mil. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Change In Inventory compare to EOLS and ELTP?
Emergent BioSolutions' Change In Inventory of $36.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Emergent BioSolutions and its competitors. Emergent BioSolutions's current Change In Inventory is $36.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Fairly Valued. The stock's GF Value™ is $5.62, compared to a current price of $5.31 — trading 5.5% below its estimated fair value. The current Change In Inventory is $36.4 Mil. Emergent BioSolutions' overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current Change In Inventory is $36.4 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (EBS) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be undervalued.
The current stock price of $5.31 is trading 5.5% below its estimated GF Value™ of $5.62.
GuruFocus considers Emergent BioSolutions to be Fairly Valued.
Key valuation signals for EBS:
Change In Inventory: $36.4 Mil
GF Value™: $5.62 vs. price of $5.31 (5.5% below fair value)
No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score
Get the complete analysis for EBS
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBS has been successfully added to your 
